I am a Pharmacist with many years of clinical and pharmaceutical industry experience. Since completing the Masters in Health Economics, my passion has been to find effective ways of demonstrating the real, and full benefit of orphan drugs used in the management of rare diseases. Aside from my work in this field, I am also a member of a scientific advisory panel for a leading hospital in the UK, with the specific focus on the development of new medicinal and procedural treatments. I am currently researching the viability of using multi-criteria decision analysis (MCDA) as a way to define the value of orphan drugs. To this end, I have developed several different MCDA frameworks to evaluate drugs, and to test various parameters, as well as the validity of the methodology.
|Last modified:||27 May 2015 4.23 p.m.|